Pharmaceuticals, Biotechnology and Life Sciences
Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), resolving all patent disputes between the two companies related to Ultomiris (ravulizumab).
Coriolis Pharma and U-Medico have announced a strategic alliance that includes an equity investment by Coriolis Pharma into U-Medico.
Qbic, an inter-university venture capital fund focusing on the transformation of technological breakthroughs into sustainable businesses, has announced the first close of its third fund at EUR 49 million.
Toxys BV, a Dutch biotech company that offers a broad spectrum of innovative in vitro toxicology solutions for the safety assessment of novel medicines, (agro)chemicals, cosmetics, and food ingredients, has announced the opening of a sales office in New York (NY) and a production facility in Gaithersburg (DE) to accelerate the company’s growth.
V-Bio Ventures has announced the completion of a EUR 80m Series B round of it’s portfolio company Precirix NV led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads.
Further positive results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy.
The Independent Data Monitoring Committee recommended that the EMPA-KIDNEY trial be stopped early, following a formal interim assessment EMPA-KIDNEY is…
Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, has signed a collaboration agreement with the DGIMI laboratory.
Temedica GmbH has announced cooperation with Bristol Myers Squibb to develop a digital companion for patients with psoriasis.
Sanofi and Blackstone (NYSE: BX) have announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma (MM).